R. Dunn

发表

Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.

Wendy S. Becker, M. Juweid, G. Griffiths, 1995, Cancer research.

Experimental studies on the role of antibody fragments in cancer radio‐immunotherapy: Influence of radiation dose and dose rate on toxicity and anti‐tumor efficacy

D. Goldenberg, R. Sharkey, T. Behr, 1998, International journal of cancer.

Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN‐14 F(ab)2

D. Goldenberg, J. Siegel, R. Sharkey, 1996, Cancer.

Anti‐carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma

A. Schauer, M. Hüfner, A. Schauer, 1997, Cancer.

Phase I/II Clinical Radioimmunotherapy with an Iodine-131 -Labeled Anti-Carcinoembryonic Antigen

Y. Vardi, M. Juweid, D. Goldenberg, 1997 .

Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.

M. Juweid, D. Goldenberg, J. Siegel, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Can occult metastases be Treated by radioimmunotherapy?

M. Juweid, D. Goldenberg, R. Sharkey, 1997, Cancer.

Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.

M. Juweid, D. Goldenberg, J. Siegel, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

99Tcm-LL1: A potential new bone marrow imaging agent

D. Goldenberg, R. Sharkey, H. Hansen, 1997, Nuclear medicine communications.

Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.

M. Juweid, R. Sharkey, H. Hansen, 1995, Cancer research.

Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.

M. Juweid, G. Griffiths, D. Goldenberg, 1995, Cancer research.

Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.

D. Goldenberg, J. Siegel, R. Sharkey, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.

Y. Vardi, M. Juweid, D. Goldenberg, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Dosimetric potential of minimal residual disease using radiolabeled antibodies

M. Juweid, T. Behr, R. Dunn, 1996 .

Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.

D. Goldenberg, J. Siegel, R. Sharkey, 1996, Cancer research.

PRECLINICAL AND CLINICAL EVALUATION OF A CDR-GRAFTED (HUMANIZED) ANTI-CARCINOEMBRYONIC ANTIGEN (CEA) MONOCLONAL ANTIBODY (MAb)

M. Juweid, G. Griffiths, D. Goldenberg, 1994 .

Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion.

Wendy S. Becker, M. Juweid, D. Goldenberg, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.

M. Juweid, D. Goldenberg, J. Siegel, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.

M. Juweid, G. Griffiths, D. Goldenberg, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?

A. Schauer, M. Hüfner, H. Becker, 1997 .

Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.

M. Juweid, D. Goldenberg, R. Sharkey, 1997, Gynecologic oncology.

Chronotolerance of experimental radioimmunotherapy: clearance, toxicity, and maximal tolerated dose of 131I-anti-carcinoembryonic antigen (CEA) IgG as a function of time of day of dosing in a murine model.

D. Goldenberg, R. Blumenthal, Z. Ying, 1999, European journal of cancer.

Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy.

M. Juweid, D. Goldenberg, R. Sharkey, 1997, Journal of nuclear medicine technology.

Thyroid radiation doses during radioimmunotherapy of CEA-expressing tumours with 131I-labelled monoclonal antibodies.

Wendy S. Becker, M. Juweid, D. Goldenberg, 1996, Nuclear medicine communications.

Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3.

D. Bajorin, C. Sternberg, M. Shi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature

Anson K. Abraham, H. Dvorak, L. Zawel, 2015, Molecular Cancer Therapeutics.

Overcoming the nephrotoxicity of radiometal‐labeled immunoconjugates

Wendy S. Becker, G. Griffiths, D. Goldenberg, 1997, Cancer.

Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22

M. Juweid, G. Griffiths, D. Goldenberg, 1997, Cancer Immunology, Immunotherapy.

Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.

F. Raue, T. Behr, R. Blumenthal, 1997, Cancer research.

Factors influencing hematologic toxicity of radioimmunotherapy with 131I‐labeled anti‐carcinoembryonic antigen antibodies

M. Juweid, D. Goldenberg, R. Sharkey, 1997, Cancer.

Neoadjuvant paclitaxel (P), carboplatin (Ca) and gemcitabine (G) in patients with locally advanced transitional cell carcinoma (TCC) of the bladder: A final report.

J. Montie, D. Smith, D. Petrylak, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes (“chimney sign”) in occult metastatic medullary thyroid cancer: A typical site of tumour manifestation?

M. Hüfner, T. Behr, R. Dunn, 1997, European Journal of Nuclear Medicine.

Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.

M. Juweid, R. Sharkey, D. Gold, 1996, Cancer research.